JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

Search

Charles River Laboratories International Inc

Chiusa

SettoreSettore sanitario

185.37 1.21

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

180.09

Massimo

185.57

Metriche Chiave

By Trading Economics

Entrata

-332M

-277M

Vendite

-11M

994M

Margine di Profitto

-27.816

Dipendenti

18,300

EBITDA

730K

198M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+7.76% upside

Dividendi

By Dow Jones

Utili prossimi

7 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

1.2B

9.2B

Apertura precedente

184.16

Chiusura precedente

185.37

Notizie sul Sentiment di mercato

By Acuity

21%

79%

67 / 348 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

23 apr 2026, 00:00 UTC

Principali Notizie su Eventi

Australian Flash PMI Bounce in April Conceals Deeper Worries

22 apr 2026, 23:33 UTC

Utili

SK Hynix Posts Record Quarterly Results Amid AI Boom

22 apr 2026, 22:40 UTC

Utili

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

22 apr 2026, 22:10 UTC

Acquisizioni, Fusioni, Takeovers

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

22 apr 2026, 21:11 UTC

Utili

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

22 apr 2026, 21:01 UTC

Utili

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

22 apr 2026, 23:46 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

22 apr 2026, 23:46 UTC

Discorsi di Mercato

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

22 apr 2026, 23:34 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

22 apr 2026, 23:16 UTC

Utili

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

22 apr 2026, 23:15 UTC

Utili

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

22 apr 2026, 22:54 UTC

Utili

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

22 apr 2026, 22:54 UTC

Utili

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

22 apr 2026, 22:52 UTC

Utili

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

22 apr 2026, 22:51 UTC

Utili

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

22 apr 2026, 22:31 UTC

Utili

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

22 apr 2026, 22:31 UTC

Utili

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

22 apr 2026, 22:30 UTC

Utili

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

22 apr 2026, 22:30 UTC

Utili

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

22 apr 2026, 22:29 UTC

Utili

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

22 apr 2026, 22:28 UTC

Utili

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

22 apr 2026, 22:28 UTC

Utili

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

22 apr 2026, 22:27 UTC

Utili

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

22 apr 2026, 22:06 UTC

Discorsi di Mercato
Utili

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

22 apr 2026, 21:55 UTC

Acquisizioni, Fusioni, Takeovers

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

22 apr 2026, 21:47 UTC

Utili

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 apr 2026, 21:37 UTC

Utili

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

22 apr 2026, 21:34 UTC

Utili

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

22 apr 2026, 21:29 UTC

Utili

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 apr 2026, 21:20 UTC

Discorsi di Mercato
Utili

Tesla Expands Manufacturing to Chips -- Market Talk

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

7.76% in crescita

Previsioni per 12 mesi

Media 197.3 USD  7.76%

Alto 235 USD

Basso 160 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

7

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

67 / 348 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat